Method of Differentiating Mammalian Progenitor Cells into Insulin Producing Pancreatic Islet Cells
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 61/055,341, filed May 22, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,605,244 | Method of Differentiating Mammalian Progenitor Cells into Insulin Producing Pancreatic Islet Cells In force · High confidence UsedRemaining | Vesta Therapeutics Inc. | In force | High confidence | ||
| US 8,877,497 | Method of Differentiating Mammalian Progenitor Cells into Insulin Producing Pancreatic Islet Cells Grace period ended Nov 4, 2026 · lapse expected · Low confidence | Vesta Therapeutics Inc. | Grace period ended Nov 4, 2026 lapse expected | Low confidence | ||
| Application 15/336,783 | Method of Differentiating Mammalian Progenitor Cells into Insulin Producing Pancreatic Islet Cells Abandoned Abandoned Dec 9, 2018 | Vesta Therapeutics Inc. | Abandoned | Abandoned Dec 9, 2018 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Vesta Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.